Clinical Trial Update: A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Becotatug Vedotin (MRG003) with Epirubicin as neoadjuvant therapy for EGFR-positive, unresectable recurrent sinonasal adenoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenoid Cystic Carcinoma
• Sinonasal Adenoid Cystic Carcinoma

Drugs mentioned

• Becotatug Vedotin (MRG003) (becotatug vedotin)
• Epirubicin (epirubicin)

Snippet

Sponsor: Eye & ENT Hospital of Fudan University | Conditions: Adenoid Cystic Carcinoma, Sinonasal Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING